EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **Reino Olavi Pelkonen**

Organisation/Company: University of Oulu

Country: Finland

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2006-12/2009	Orion Pharma	ORM-12741: ad-hoc expertise on preclinical PK properties and metabolism	An antipsychotic drug (I do not know the generic name)
01/2006-12/2007	Orion Pharma	Dextor (dexmedetomidine)	anesthetic adjuvant

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
01/1999-12/2004	Pfizer	Celebra	NSAID
01/2000-12/2002	UCB Pharma	Zyxal	antihistamine

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I retired on 01/05/2010 and now have an emeritus position at the University of Oulu. Research consortium coordinated by the University of Oulu and involving Orion Pharma, which was previously under my leadership, was officially led by my successor after my retirement. The consortium finished officially on September 9, 2011. Since my retirement, I have had supervisory roles in PhD projects which have been based on consortia involving collaboration with Orion Pharma and SMEs (Hormos Medical, AdmeScope); I have had no financial control or gains. The last PhD student under my (co-)supervision (Jouko Uusitalo, M.Sc.) defended his thesis on 04/12/2015.

Since July 2015 I have been a member (toxicology expert) of the Pesticide Panel (PPR) of EFSA, Parma, Italy, and this position is now up to July 2021.

Lectures in various symposia or workshops organised by Medical Faculties in Oulu, Helsinki, Kuopio and Tampere, Scientific and Medical Societies (e.g. Finnish Physicians Society, Medical Society Duodecim) or other academic organisations with sponsorship from various pharmaceutical companies (Santen, GSK, Pfizer, Leiras, Orion Pharma, AstraZeneca). The latest lectures were in Workshop of Professional Medical Training (Helsinki, Finland) on December 2014 and in the meeting of the Finnish Societies of Pharmacology, Clinical Pharmacology and Toxicology (Helsinki, Finland) on April 2015. Thereafter I have had no analogous lectures.

Invited presentations in international conferences, congresses and workshops organized and/or sponsored by international societies, e.g. International Union of Pharmacology and Clinical Pharmacology (IUPHAR), International Society of the Study of Xenobiotics (ISSX) etc. No honoraria are involved in these scientific meetings. The latest talks and/or chairs were in the EUROTOX2015, Porto, Portugal, EUROTOX2016, Sevilla, Spain, ESTIV2016, Juan-les-Pins, France, 2nd German Pharm-Tox Summit, Heidelberg, Germany, The 16th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), 2017, Guangzhou, China, Pharmacology2017, BPS, London, UK. ESTIV2018, Berlin, Germany, 3rd SRACD Symposium, Budapest, Hungary. Usually there are a large number of sponsors for these congresses, including several pharmaceutical companies.

I belong currently to the International Editorial Advisory Council of the British Journal of Clinical Pharmacology (British Pharmacological Society, London, UK) and have been a Council Member of the International Society for the Study of Xenobiotics (ISSX, Washington, DC, USA) on 2011-2012.

I have had and have advisory roles in EU Framework Programme (FP) proposals in which also drug companies or CROs are partners. I have participated in preparatory meetings, but no honoraria have been paid. The latest preparatory meeting of the prospective EU FP proposal was in the AstraZeneca (Mölndal, Sweden) premises on April 2014 and 2 scientific advisory board (SAB) meetings of 2 consortia are projected for the first part of 2020.

I was a co-founder of Pharmatest Services Ltd, a small spin-off company based in Turku, Finland, and serving various chemical -related industries regarding risk assessment and drug discovery companies for screening chemical libraries. I have had no activities with the company since 2008.

I was a co-founder of Novamass Analytical Ltd, a small spin-off company based in Oulu, Finland, and serving chemical -related industries, including drug development companies in early discovery and development phases. I have had no activities with the company since 2009. Furthermore, in 2008 the company was merged with Systems Biology Worldwide Ltd, (SBW) a company owned by The Helsinki University Foundation), which meant the termination of my involvement with the company. SBW became bankrupt late 2013.

I was a scientific adviser of Xemet Ltd until 2010 (unpaid). Xemet Ltd develops various modelling and simulation tools for technology companies and my involvement was based on my experience in biological modelling and simulation studies.

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Reino Olavi Pelkonen
Date:	2019-10-09

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template